A Randomized Controlled Trial of Amantadine in Fatigue Associated With Multiple Sclerosis

W. Hader; P. Duquette; A. Auty Winnipeg; S. Hashimoto; J. Noseworthy; G. Sawa; D. Brunet; R. Nelson; T. Gray; G. Klein; G. Francis; Y. Lapierre; B. Weinshenker; W. Barkas; S. Philips; M. Girard; T. J. Murray

doi:10.1017/S0317167100026603

A Randomized Controlled Trial of Amantadine in Fatigue Associated With Multiple Sclerosis

W. Hader, P. Duquette, A. Auty Winnipeg, S. Hashimoto, J. Noseworthy, G. Sawa, D. Brunet, R. Nelson, T. Gray, G. Klein, G. Francis, Y. Lapierre, B. Weinshenker, W. Barkas, S. Philips, M. Girard, T. J. Murray

Neurology

Research output: Contribution to journal › Article › peer-review

126 Scopus citations

Abstract

One hundred and fifteen patients with definite multiple sclerosis (M.S.) and chronic persistent fatigue were studied. This ten-week cross-over study consisted of a 2-week baseline period and two 3-week treatment periods separated by a 2-week washout. Patients received either amantadine 100 mg bid or matching placebo capsules. Fatigue, the effect of fatigue on an individually pre-selected activity and its effect on activities of daily living, were evaluated. Amantadine produced a small but statistically significant decrease in fatigue. An important placebo effect was noted. Mean fatigue during the washout period was lower than during the placebo run-in period, independently of which treatment had been given first. Side effects were numerous both on amantadine and on placebo. Only insomnia was significantly more common with amantadine.

Original language	English (US)
Pages (from-to)	273-278
Number of pages	6
Journal	Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
Volume	14
Issue number	3
DOIs	https://doi.org/10.1017/S0317167100026603
State	Published - Aug 1987

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1017/S0317167100026603

Cite this

Hader, W., Duquette, P., Winnipeg, A. A., Hashimoto, S., Noseworthy, J., Sawa, G., Brunet, D., Nelson, R., Gray, T., Klein, G., Francis, G., Lapierre, Y., Weinshenker, B., Barkas, W., Philips, S., Girard, M., & Murray, T. J. (1987). A Randomized Controlled Trial of Amantadine in Fatigue Associated With Multiple Sclerosis. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 14(3), 273-278. https://doi.org/10.1017/S0317167100026603

Hader, W, Duquette, P, Winnipeg, AA, Hashimoto, S, Noseworthy, J, Sawa, G, Brunet, D, Nelson, R, Gray, T, Klein, G, Francis, G, Lapierre, Y, Weinshenker, B, Barkas, W, Philips, S, Girard, M & Murray, TJ 1987, 'A Randomized Controlled Trial of Amantadine in Fatigue Associated With Multiple Sclerosis', Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, vol. 14, no. 3, pp. 273-278. https://doi.org/10.1017/S0317167100026603

@article{1d5a60a23dd54c8b991e97d2fa9aebd9,

title = "A Randomized Controlled Trial of Amantadine in Fatigue Associated With Multiple Sclerosis",

abstract = "One hundred and fifteen patients with definite multiple sclerosis (M.S.) and chronic persistent fatigue were studied. This ten-week cross-over study consisted of a 2-week baseline period and two 3-week treatment periods separated by a 2-week washout. Patients received either amantadine 100 mg bid or matching placebo capsules. Fatigue, the effect of fatigue on an individually pre-selected activity and its effect on activities of daily living, were evaluated. Amantadine produced a small but statistically significant decrease in fatigue. An important placebo effect was noted. Mean fatigue during the washout period was lower than during the placebo run-in period, independently of which treatment had been given first. Side effects were numerous both on amantadine and on placebo. Only insomnia was significantly more common with amantadine.",

author = "W. Hader and P. Duquette and Winnipeg, {A. Auty} and S. Hashimoto and J. Noseworthy and G. Sawa and D. Brunet and R. Nelson and T. Gray and G. Klein and G. Francis and Y. Lapierre and B. Weinshenker and W. Barkas and S. Philips and M. Girard and Murray, {T. J.}",

year = "1987",

month = aug,

doi = "10.1017/S0317167100026603",

language = "English (US)",

volume = "14",

pages = "273--278",

journal = "Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques",

issn = "0317-1671",

publisher = "Canadian Journal of Neurological Sciences",

number = "3",

}

TY - JOUR

T1 - A Randomized Controlled Trial of Amantadine in Fatigue Associated With Multiple Sclerosis

AU - Hader, W.

AU - Duquette, P.

AU - Winnipeg, A. Auty

AU - Hashimoto, S.

AU - Noseworthy, J.

AU - Sawa, G.

AU - Brunet, D.

AU - Nelson, R.

AU - Gray, T.

AU - Klein, G.

AU - Francis, G.

AU - Lapierre, Y.

AU - Weinshenker, B.

AU - Barkas, W.

AU - Philips, S.

AU - Girard, M.

AU - Murray, T. J.

PY - 1987/8

Y1 - 1987/8

N2 - One hundred and fifteen patients with definite multiple sclerosis (M.S.) and chronic persistent fatigue were studied. This ten-week cross-over study consisted of a 2-week baseline period and two 3-week treatment periods separated by a 2-week washout. Patients received either amantadine 100 mg bid or matching placebo capsules. Fatigue, the effect of fatigue on an individually pre-selected activity and its effect on activities of daily living, were evaluated. Amantadine produced a small but statistically significant decrease in fatigue. An important placebo effect was noted. Mean fatigue during the washout period was lower than during the placebo run-in period, independently of which treatment had been given first. Side effects were numerous both on amantadine and on placebo. Only insomnia was significantly more common with amantadine.

AB - One hundred and fifteen patients with definite multiple sclerosis (M.S.) and chronic persistent fatigue were studied. This ten-week cross-over study consisted of a 2-week baseline period and two 3-week treatment periods separated by a 2-week washout. Patients received either amantadine 100 mg bid or matching placebo capsules. Fatigue, the effect of fatigue on an individually pre-selected activity and its effect on activities of daily living, were evaluated. Amantadine produced a small but statistically significant decrease in fatigue. An important placebo effect was noted. Mean fatigue during the washout period was lower than during the placebo run-in period, independently of which treatment had been given first. Side effects were numerous both on amantadine and on placebo. Only insomnia was significantly more common with amantadine.

UR - http://www.scopus.com/inward/record.url?scp=0023231728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023231728&partnerID=8YFLogxK

U2 - 10.1017/S0317167100026603

DO - 10.1017/S0317167100026603

M3 - Article

C2 - 2889518

AN - SCOPUS:0023231728

SN - 0317-1671

VL - 14

SP - 273

EP - 278

JO - Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques

JF - Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques

IS - 3

ER -

A Randomized Controlled Trial of Amantadine in Fatigue Associated With Multiple Sclerosis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this